RegenLab USA, a pioneering medical device company specializing in autologous regenerative medicine and tissue engineering, not only cut the ribbon Friday on its state-of-the-art R&D and manufacturing facility in Jersey City, it reaffirmed its plan to hire 150 workers in the next three years.
The facility, located at 95 Greene Street, will support advancements in aesthetics, orthopedics, gynecology, and tissue engineering, leveraging the company’s patented technology in blood component separation, backed by over 150 international patents and more than 300 scientific publications.
RegenLab USA plans to hire 50 new employees annually, reaching approximately 200 employees over the next three years. The company’s new facility will develop and manufacture advanced medical solutions that improve patient outcomes in unmet needs of regenerative medicine.
Gov. Phil Murphy said RegenLab’s decision to expand in Jersey City is a testament to New Jersey’s standing as a global leader in life sciences and innovation.
“Our state offers the talent, infrastructure, and collaborative research ecosystem that pioneering companies need to grow and thrive,” he said. “We are proud to welcome RegenLab USA as they invest in our communities, create high-quality jobs, and develop groundbreaking technologies that improve lives around the world.”
The company selected Thor Equities’ premier life sciences space in the historic Colgate-Palmolive headquarters, a prime location with proximity to New York City and Newark International Airport.
RegenLab Founder and President Antoine Turzi said moving to New Jersey from Brooklyn made sense on a number of levels.
“The presence of multiple academic institutions in New Jersey provides invaluable collaboration opportunities for in vitro and ex vivo studies that will accelerate our research,” he said.
“We chose New Jersey because of its unmatched access to scientific talent, a thriving innovation ecosystem, and a strategic location near major metropolitan hubs. The state’s long-standing leadership in life sciences, coupled with a business-friendly environment, makes it the ideal place for RegenLab USA to grow and bring next-generation regenerative therapies to patients around the world.”
Wes Mathews, Choose New Jersey CEO was thrilled to welcome RegenLab.
“New Jersey’s life sciences ecosystem continues to attract cutting-edge companies like RegenLab USA,” he said. “With access to world-class research institutions, top-tier talent, and an innovation-friendly business environment, New Jersey is the ideal home for companies at the forefront of medical advancements, and we are glad RegenLab USA is calling Jersey City home.”
